問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林哲弘

Recruiting

List

152Cases

2024-03-01 - 2030-07-16

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-03-01 - 2026-12-31

Phase I/II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-11-01 - 2022-08-29

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2020-10-01 - 2025-12-31

Phase I

An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420 as a Single Agent in Hematologic and Molecular Relapsed/Refractory Acute Myeloid Leukemia

  • Condition/Disease

    Relapsed/Refractory Acute Myeloid Leukemia

  • Test Drug

    RO7283420

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

2022-11-01 - 2024-09-30

Phase I

An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

  • Condition/Disease

    Leukemia, Myeloid, Acute

  • Test Drug

    H3B-8800 (RVT-2001)

Participate Sites
5Sites

Recruiting5Sites

2017-01-01 - 2021-12-31

Phase III

A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations

  • Condition/Disease

    Metastatic Castration-Resistant Prostate Cancer

  • Test Drug

    Olaparib

Participate Sites
9Sites

Recruiting5Sites

Terminated4Sites

2019-10-01 - 2023-01-13

Phase II

A phase 2, multicenter open-label, non-randomized study of bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer who have progressed on or after at least one prior standard therapy

  • Condition/Disease

    Gastric Cancer / GastroEsophageal Cancer

  • Test Drug

    Bavituximab

Participate Sites
4Sites

Recruiting4Sites

2021-08-15 - 2024-08-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2018-12-18 - 2021-12-31

Phase I

A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    ASP8374(PTZ-201)

Participate Sites
4Sites

Recruiting3Sites

邱昌芳
China Medical University Hospital-Taipei

未分科

2020-10-01 - 2023-09-30

Phase I

A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects

  • Condition/Disease

    HER2 expressing or mutated Advanced Solid Tumors

  • Test Drug

    Drug: SHR-A1811

Participate Sites
3Sites

Recruiting3Sites

1 12 13 14 15 16
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB